<DOC>
	<DOCNO>NCT02985736</DOCNO>
	<brief_summary>A single center , study 20 subject assess 4 week therapy Topicort® twice daily BID 12 week twice daily 2 consecutive day patient scalp psoriasis</brief_summary>
	<brief_title>Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray</brief_title>
	<detailed_description>All patient receive Topicort® twcie daily ( BID ) 4 week . After week 4 patient receive Topicort® twice weekly ( consecutive day ) 12 week , Patients treat body area affect plaque psoriasis Topicort® study period ( excludes face , groin , axilla )</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Desoximetasone</mesh_term>
	<criteria>1 . Male female adult ≥ 18 year age . 2 . Diagnosis chronic plaquetype scalp psoriasis . 3 . IGA mild great ( scalp ) determine screen 4 . Scalp surface area 30 % great determine screen 5 . Able give write informed consent prior performance study related procedure . 6 . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . FCBP engage activity conception possible must use one approve contraceptive option : hormonal contraception ; intrauterine device ( IUD ) ; tubal ligation ; partner 's vasectomy ; Male female condom , diaphragm spermicide , cervical cap spermicide , contraceptive sponge spermicide . 7 . Subject must general good health ( except psoriasis ) judge Investigator , base medical history , physical examination . 1 . &lt; 30 % scalp surface area 2 . Scalp Investigator global assessment ( IGA ) clear almost clear time screen 3 . Any condition , would place subject unacceptable risk he/she participate study . 4 . Pregnant breast feeding , consider become pregnant study . 5 . Use investigational drug within 4 week prior randomization , within 5 pharmacokinetic/pharmacodynamic half life , know ( whichever longer ) . 6 . Use oral systemic medication treatment psoriasis within 4 week ( include , limited , oral corticosteroid , methotrexate , acitretin , apremilast cyclosporine ) . 7 . Use ustekinumab and/or antiIL17 ( interleukin 17 ) biologic therapy within 24 week experimental commercially available biologic immune modulator ( ) within 12 week prior first IP dose . 8 . Patient use topical therapy treat within 2 week Baseline Visit ( include permit topical therapy face , groin axilla ) . 9 . Patient receive ultraviolet B , UVB phototherapy within 2 week Baseline . 10 . Patient receive psoralen Ultraviolet A , PUVA phototherapy within 4 week Baseline . 11 . Patient known hypersensitivity excipients Topicort Spray® state label .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>